Rochester General Hospital, an affiliate hospital of Rochester Regional Health, is a 528-bed tertiary care hospital, located in Rochester, New York. Rochester General Hospital has been serving the residents of the Rochester Region and beyond since 1847.

There are 528 beds in Rochester Regional Health.

During the past decade, Rochester Regional Health conducted 11 clinical trials. In the 10-year time frame, 11 clinical trials started and 3 clinical trials were completed, i.e. on average, 27.3% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 2 clinical trials were completed. i.e. 40% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Rochester Regional Health" #1 sponsor was "Pfizer" with 2 trials, followed by "University of Rochester" with 2 trials sponsored, "Cumberland Pharmaceuticals" with 1 trials sponsored, "Guard Therapeutics AB" with 1 trials sponsored and "HealthCore-NERI" with 1 trials sponsored. Other sponsors include -1 different institutions and companies that sponsored additional 9 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Rochester Regional Health" #1 collaborator was "ALN Implants Chirurgicaux" with 1 trials as a collaborator, "Argon Medical Devices" with 1 trials as a collaborator, "B. Braun Interventional Systems, Inc" with 1 trials as a collaborator, "Bard Peripheral Vascular, Inc." with 1 trials as a collaborator and "Biosense Webster, Inc." with 1 trials as a collaborator. Other collaborators include 5 different institutions and companies that were collaborators in the rest 15 trials.

According to Clinical.Site data, the most researched conditions in "Rochester Regional Health" are "ALK-positive Non Small Cell Lung Cancer (NSCLC) and ROS1-positive NSCLC" (1 trials), "Acute Kidney Injury" (1 trials), "Allergic Reaction" (1 trials), "Asthma, Aspirin-Induced" (1 trials) and "COVID-19" (1 trials). Many other conditions were trialed in "Rochester Regional Health" in a lesser frequency.

Most popular intervention types in "Rochester Regional Health" are "Drug" (6 trials), "Biological" (2 trials), "Device" (2 trials) and "Procedure" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (4 trials), "Crizotinib" (1 trials), "DUPIXENT®" (1 trials), "Formulation A" (1 trials) and "Formulation B" (1 trials). Other intervention names were less common.

The vast majority of trials in "Rochester Regional Health" are 11 trials for "All" genders.

Currently, there are NaN active trials in "Rochester Regional Health". undefined are not yet recruiting, 3 are recruiting, 3 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Rochester Regional Health, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Rochester Regional Health, 0 "Phase 1" clinical trials were conducted, 5 "Phase 2" clinical trials and 1 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 2 trials that are defined as “Not Applicable".

Rochester Regional Health has several departments that took part in Clinical trials: "Lipson Cancer and Blood Center at Rochester General Hospital" - 27 trials, "Finger Lakes Radiation Oncology Center" - 19 trials, "St Mary's Hosp (Univ of Rochester/Infectious Diseases)" - 8 trials, "Rochester General Hospital Infectious Disease" - 2 trials, "Rochester Gastroenterology: Devgun Surinder MD" - 2 trials, "Unity Hospital" - 2 trials, "Unity Spine Center" - 2 trials, "The Center for Dermatology at Lifetime Health" - 2 trials